Viewing Study NCT04770857


Ignite Creation Date: 2025-12-24 @ 6:59 PM
Ignite Modification Date: 2025-12-29 @ 9:56 PM
Study NCT ID: NCT04770857
Status: UNKNOWN
Last Update Posted: 2021-07-29
First Post: 2021-02-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Sponsor: Nicola Frei
Organization:

Study Overview

Official Title: Evaluation of Post-Post-Endoscopic Retrograde Cholangiopancreaticography Pain (ERCP) as a Predictor for Post-ERCP Pancreatitis
Status: UNKNOWN
Status Verified Date: 2021-07
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PEP-PREPARE
Brief Summary: Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from \< 2% up to 40%.

Based upon data from studies that have included unselected patients, post-ercp pancreatitis (PEP) is mild, moderate, and severe in 45%, 44%, and 11% of cases, respectively. Dysfunction of the sphincter Oddi, female gender, younger age, previous history of pancreatitis, prolonged procedure time and pancreatic guidewire passages are well-known independent risk factors for PEP.

This study will assess whether the development of PEP can be predicted by Visual analogue scale (VAS) level 1 hour after ERCP.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: